
ACT Brief: Patient Trial Conversations, Measuring Site Burden, and Cosentyx and Wilserdly Approval
11/18/2026
0:00
1:39
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.
More episodes from "Applied Clinical Trials"



Don't miss an episode of “Applied Clinical Trials” and subscribe to it in the GetPodcast app.








